Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course adjuvant tislelizumab after TACE + MWA in early-stage HCC
ChiCTR2500110080Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Yanbian University
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in hepatocellular carcinoma (HCC), sponsored by The Affiliated Hospital of Yanbian University. Primary endpoints: Progression-Free Survival (PFS) and Recurrence-Free Survival (RFS). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500110080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110080.